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Abstract
Background: Current treatments for osteoporosis are associated with various side effects and do not prevent the
age-related decrease in osteoblast number. The objective of this study was to evaluate the effects of iQPR-H2Oo n
osteogenesis.
Methods: Mouse fibroblast NIH3T3 and pre-osteoblastic MC3T3-E1 cells were cultured in medium prepared with
iQPR-H2O or unprocessed mineral water (control cells), and proliferation and differentiation were assessed by MTT
and alkaline phosphatase assay, respectively. Mineral deposition by the cells was determined using Alizarin red S
staining. A mouse model of osteoporosis, ovariectomized SAMP8 mice, was used to evaluate the effects of iQPR-
H2O on osteogenesis in vivo. Mice were given either iQPR-H2O or unprocessed mineral water (control group) for
four months after which bone mass density (BMD) measurements were made using a bone densitometer and
hematoxylin and eosin staining of bone samples.
Results: NIH3T3 cells grown in medium prepared with iQPR-H2O exhibited significantly greater proliferation.
NIH3T3 and MC3T3-E1 cells demonstrated a significant increase in alkaline phosphatase levels in the iQPR-H2O
group. MC3T3-E1 cells showed mineralization at day 28. mRNA expression levels of both osteopontin and runt-
related transcription factor 2 in MC3T3-E1 cells were higher in the iQPR-H2O group compared with the control
group. After four months, significantly greater bone regeneration was evident in ovariectomized SAMP8 mice
administered iQPR-H2O as compared with control group.
Conclusions: iQPR-H2O may reduce the symptoms of osteoporosis by improving osteogenesis.
Keywords: osteoporosis, Quantum Persistent Reflection, mouse fibroblasts, senescence-accelerated mice, bone
mass density
Background
Osteoporosis is a disease characterized by abnormal
bone metabolism caused by an imbalance in bone remo-
deling, which reduces bone density and increases the
incidence of fractures [1,2]. Current treatments for
osteoporosis inhibit bone density loss through pharma-
ceutical and non-pharmaceutical methods [3,4]. Non-
pharmaceutical treatments include calcium and vitamin
D supplementation [5-8] and regular weight-bearing
exercise [9]. Pharmaceutical treatments include bispho-
sphonates, hormones, parathyroid hormones, and
calcitonin, which inhibit resorption or stimulate bone
generation [10]. However, adverse effects, including
bone necrosis, hyperparathyroidism, vein thrombosis,
hot flashes, and foot cramps, have been reported as a
consequence of pharmaceutical treatments [11]. In addi-
tion, current treatments do not address the fundamental
cause of osteoporosis, namely, bone loss due to an age-
related reduction in the number of osteoblasts [12].
Infinitesimal Quantum persistent reflection (QPR™)
element water(iQPR-H2O) is prepared by a steady device
of matter energy, which is a patented technology devel-
oped by Mr. Lam Gow Lin (New Technology Number
M 273565; United States Patent Application
20060099120; http://www.freepatentsonline.com/y2006/
0099120.html) based on the theory of controlling “time
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[13]. Specifically, in steady device of matter energy, a
reaction column is programmed such that invisible light
can cause interference, superposition, reflection, and dis-
persion for a set amount of time and in a fixed space.
Upon treatment, bonds of molecules are broken, thereby
producing elements and small molecules after which
they are rearranged, increasing the energy state of mat-
ter. This treatment can be applied to drinking water,
cosmetics, wine, and medical treatments, thereby
increasing their energy states.
The present study tested the hypothesis that iQPR-
H2O would promote bone deposition in osteoporosis.
Therefore, the effects of iQPR-H2O on mouse fibroblast
(NIH3T3) and osteoblastic (MC3T3-E1) cell lines were
examined. NIH3T3 cells have the capacity to differenti-
ate into osteoblasts [12,14,15]. Specifically, cell prolifera-
tion, differentiation, and mineral deposition in response
to iQPR-H2O were assessed. In addition, the effects of
iQPR-H2O on bone mineral density (BMD) using a
mouse model of osteoporosis, ovariectomized SAMP8
(OVX-SAMP8) mice [16,17], was analyzed.
Methods
Characterization of iQPR-H2O
The water was analyzed by SGS Taiwan Environmental
Lab (Taipei, Taiwan). Unprocessed mineral water and
iQPR-H2O have densities of 0.9961 and 0.9870, respec-
tively. Processing of the water decreased the pH from
6.23 to 6.16. No significant changes in boiling point were
observed upon processing. Conductivity, total dissolved
solid, salinity, dissolved oxygen, and oxidization-reduc-
tion potentials were measured using a YSI Professional
Plus handheld multiparameter instrument (YSI Incorpo-
rated, Yellow Springs, OH, USA) at a water temperature
of 24°C. Although no significant changes in conductivity,
total dissolved solid, and salinity were observed, dissolved
oxygen were increased from 7.11 to 9.15 mg/L, and oxidi-
zation-reduction potentials were reduced from 265.0 to
239.1 after processing. The elements within both types of
water were measured by inductively coupled plasma
mass spectroscopy (ICP-MS; Table 1).
In vitro studies
Proliferation and viability
NIH3T3 fibroblast (ATCC CRL-1658) and MC3T3-E1
pre-osteoblastic (ATCC CRL-2593) cells (provided by
the cell line center, China Medical University, Taichung,
Taiwan) were cultured in 96-well plates (2 × 10
3 cells/
well) in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum and prepared
with sterilized iQPR-H2O or unprocessed mineral water
(control medium) for 0, 1, 3, 5, 7, or 9 days. Cell prolif-
eration at the end of each time point was determined
using a Cell Growth Determination Kit (Sigma-Aldrich,
St. Louis, MO) following manufacturer’s instructions.
Differentiation
NIH3T3 and MC3T3-E1 cells were cultured in 6-well
plates (1 × 10
5 cells/well) in iQPR-H2O-containing or con-
trol media for 0, 1, 3, 5, or 7 days. Differentiation was
determined at the end of each time point by assessing
alkaline phosphatase (ALP) levels as previously described
[18]. Exposure of cells to iQPR-H2O was extended to 14
and 28 days after which ALP expression was measured.
mRNA Expression of osteopontin and runt-related
transcription factor 2
mRNA expression levels of osteopontin (OPN) and runt-
related transcription factor 2 (RUNX2) were assessed in
MC3T3-E1 cells after 28 days of culture in iQPR-H2O-
containing or control media. Total RNA was extracted
from cells using TRIzol reagent (Invitrogen Life Technol-
ogies, Carlsbad, CA, USA). Gene expression levels were
measured by reverse-transcription polymerase chain
reaction (PCR). The following PCR primers were used:
OPN forward primer, 5’-ATGAGATTGGCAGT-
GATT-3’;
OPN reverse primer, 5’-GTTGACCTCAGAAGATGA-3’;
RUNX2 forward primer, 5’-ACTTTCTCCAGGAA-
GACTGC-3’;
RUNX2 reverse primer, 5’-GCTGTTGTTGCTGTT
GCTGT-3’;
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
forward primer 5’, GCTCTCCAGAACATCATCC
CTGCC-3’;
GAPDH reverse primer, 5’-CGTTGTCATACCAG-
GAAATGAGCTT-3’.
Table 1 Elements in iQPR-H2O: a comparison with
unprocessed mineral water
Elements (ppb) Unprocessed mineral water IQPR-H2O
Boron 8.87 11.7
Calcium 51.22 21.9
Cobalt 0.22 0.03
Copper 0.23 0.04
Iron 0.38 0.10
Germanium 0.11 0.01
Potassium 37.22 48.50
Magnesium 19.25 23.4
Manganese 0.02 0.06
Sodium 416.5 176
Nickel 0.14 0.02
Phosphorus 6.96 4.38
Selenium 0.33 0.05
Zinc 0.06 0.20
Iodine 36 162
Silicon 173 289
Oxygen 8.50 8.40
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on 1% agarose gels (Agarose I; AMRESCO, Solon,
OH, USA) and visualized using ethidium bromide
staining.
Cell mineralization
MC3T3-E1 cells were cultured in 2-cm diameter plates
(1 × 10
4 cells/plate) in iQPR-H2O-containing or control
media for 28 days. Cell mineralization was determined
by staining with Alizarin red S (Sigma-Aldrich) as pre-
viously described [19].
In vivo studies
Animals and preparation
All animal experiments were approved by the Labora-
tory Animal Research Committee of Taipei Medical
University. Female SAMP8 mice (Providence University,
Taichung, Taiwan) were maintained in a clean environ-
ment with a temperature between 22 to 24°C and 50%
humidity and received food (BioLASCO Taiwan Co.,
Ltd., Taipei, Taiwan) and regular drinking water ad libi-
tum. Mice were ovariectomized (OVX) at four months
o fa g et oi n d u c eo s t e o p o r o s i sf o l l o w i n gt h ep r o t o c o l
described by Lo et al. [12]. Two weeks after the surgery
(T = 0), OVX-SAMP8 mice received iQPR-H2O (experi-
mental group; n = 6) or unprocessed mineral water
(control group; n = 6) for four months. BMD was deter-
mined each month. After four months, the mice were
sacrificed, and bone samples were obtained for further
analysis.
Bone mass density analysis
Baseline BMD was measured two weeks after the
SAMP8 mice were ovariectomized (T = 0) and at one-
month intervals for four months using the XR-36 bone
densitometer (Norland Products Inc., Cranbury, NJ).
Data were acquired using scanner software version 2.0.0
(Norland Products Inc., Cranbury, NJ) and analyzed
using host software version 2.5.3 (Norland Products
Inc., Cranbury, NJ). Changes in spine, knee, and femur
BMD (g/cm
2) were compared with the baseline BMD
values.
Hematoxylin and eosin (H&E) staining
Subsets of six mice were sacrificed two weeks after ovar-
iectomy (T = 0) and one and four months later. After
the mice were sacrificed, spine, femur, and tibial bone
(knee) samples were removed and fixed in 10% formal-
dehyde. Samples were softened in decalcification fluid,
embedded in paraffin, and sectioned (10 μmt h i c k )f o r
H&E staining. Three sections, which represent three
locations in bone, were examined using a microscopic
digital camera (Pixera Penguin 150CL Cooled CCD, San
Jose, CA), and the area of interest was measured and
analyzed.
Statistical analysis
Normally distributed continuous variables between the
control and iQPR-H2O groups were compared using
independent two-sample t-test. Data are presented as
means ± standard deviation (SD). All statistical assess-
ments were two-sided and evaluated at the 0.05 level of
significant difference. Statistical analyses were performed
using SPSS 15.0 statistics software (SPSS Inc, Chicago,
IL).
Results
Effect of iQPR-H2O on NIH3T3 cell proliferation
Increased NIH3T3 cell proliferation was observed in
cells cultured in medium prepared with iQPR-H2O (Fig-
ure 1). Cells cultured in media prepared with iQPR-H2O
attained confluence after seven days whereas control
cells were not confluent at this time.
Effect of iQPR-H2O on NIH3T3 and MC3T3-E1 cell
differentiation
The effect of iQPR-H2O on NIH3T3 and MC3T3-E1
cell differentiation was determined by measuring ALP
levels after short-term (1, 3, 5, and 7 days) or long-term
(14 and 28 days) exposure to iQPR-H2O-containing
medium. There were no significant differences in ALP
levels between the iQPR-H2O and control groups fol-
lowing short-term culture of NIH3T3 cells (Figure 2A).
However, after 14 and 28 days culture of NIH3T3 cells,
significantly greater ALP levels were evident in the
iQPR-H2O group compared with those in the control
group (P < 0.05, Figure 2B). For MC3T3-E1 pre-osteo-
blastic cells, there were significantly greater ALP levels
evident in the iQPR-H2O group compared with the con-
trol group from 7 days onwards (P < 0.05, Figure 3A).
Both OPN and RUNX2 are the markers of osteoblast
differentiation. The mRNA expression levels of both
OPN and RUNX2 were higher in the iQPR-H2Og r o u p
compared with the control group (Figure 3B).
Effect of iQPR-H2O on MC3T3-E1 cell mineralization
The effects of iQPR-H2O on MC3T3-E1 cell mineraliza-
tion were assessed using Alizarin red S staining, which
identifies calcium-content within tissue. After 28 days,
increased Alizarin red S staining was observed in the
iQPR-H2O group (Figure 4) compared with the control
group.
Effect of iQPR-H2O on BMD in OVX-SAMP8 mice
Spine, left knee, right knee, left femur, and right femur
bone densities were determined in OVX-SAMP8 mice
given iQPR-H2O or unprocessed mineral water (con-
trol). At the zero-, two-, and three-month time points,
there were no significant between group differences in
bone density; however, after four months, significantly
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ted mice (Figure 5). Specifically, after four months,
BMD levels were significantly higher in spine, right
knee, and left and right femur bone samples obtained
from mice receiving iQPR-H2O as compared with those
obtained from control mice (all P < 0.05; Figure 5A, C,
D ,E ) .N od i f f e r e n c ei nl e f tk n e eB M Dw a so b s e r v e d
between the groups (Figure 5B).
Effect of iQPR-H2O on bone density in OVX-SAMP8 mice
as determined by H&E analysis
Bone samples were obtained from OVX-SAMP8 mice
given iQPR-H2O or control water for four months and
stained with H&E. As shown in Figure 6A, representa-
tive microscopic images of (1) lumbar spine (left and
right panels), (2) left knee (top and bottom panels), and
(3) right knee sections (top and bottom panels) were
Figure 1 Effects of iQPR-H2O on NIH3T3 cell proliferation. Cells cultured in medium prepared with iQPR-H2O or unprocessed mineral water
(control) were analyzed for cell proliferation by MTT assay after 1, 3, 5, 7, and 9 days of culture. Data represent means ± SD of triplicates.
Figure 2 Effects of iQPR-H2O on NIH3T3 cell differentiation. ALP levels were determined in cells cultured in medium prepared with iQPR-
H2O or unprocessed mineral water (control) after 1, 3, 5, and 7 days (A), or after 14 and 28 days (B). Data represent means ± SD of triplicates. *P
<0.05, as determined by independent two-sample t-tests.
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tively. After four months, mice receiving iQPR-H2O
exhibited significantly higher BMDs in the spine and
both knees compared with control group mice (all P <
0.05; Figure 6B). In addition, bone tissue biopsies at five
locations revealed increased trabecular bone in iQPR-
H2O-treated mice (data not shown).
Discussion
The effects of iQPR-H2O on cell proliferation, differen-
tiation and mineral deposition as well as bone formation
were analyzed in this study under in vitro condition
using NIH3T3 fibroblast and MC3T3-E1 osteoblastic
cell lines, and under in vivo condition using mouse
model of osteoporosis as described previously [12].
NIH3T3 cells treated with iQPR-H2O displayed an
increased ability to proliferate. Both NIH3T3 and
MC3T3-E1 cells in iQPR-H2O-containing medium
showed higher levels of differentiation compared with
control cells. In vivo studies revealed that iQPR-H2O
increased BMD in OVX-SAMP8 mice, indicating that
under long-term induction, osteoblasts may be capable
of differentiation and improving the symptoms of
osteoporosis.
MC3T3-E1 cells showed a sign of differentiation i.e.
significantly higher ALP level than control, 7 days after
culture in iQPR-H2O-containing medium. Further,
expression of both OPN and RUNX2 mRNA was higher
in the iQPR-H2O group compared with the control
group after 28 days of culture. This observation is simi-
lar to that from a previous report showing that ALP
levels were significantly higher 7 days after MC3T3-E1
cells were stimulated with ascorbic acid and b-glycero-
phosphate [20]. OPN has been reported to modulate
both mineralization and bone resorption, and RUNX2 is
one of the major regulators of OPN in osteoblastic cells
Figure 3 Effects of iQPR-H2O on MC3T3-E1 cell differentiation. ALP levels were determined in cells cultured in medium prepared with iQPR-
H2O or unprocessed mineral water (control) after 1, 3, 5, and 7 days, 14 and 28 days (A). Data represent means ± SD of triplicates. *P< 0.05, as
determined by independent two-sample t-tests. (B) Effect of iQPR-H2O on OPN and RUNX2 mRNA expression in MC3T3-E1 cell cultured in the
presence (+) or absence (-) of iQPR-H2O for 10 days. Expression of GAPDH was determined as a loading control.
Figure 4 Effects of iQPR-H2O on mineral deposition in MC3T3-E1 cells. Cells cultured in medium prepared with unprocessed mineral water
(control) (A) or iQPR-H2O (B) were analyzed for mineralization by assessing Alizarin red S staining (orange-red) using light microscopy after 28
days of culture. 100× magnification.
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Page 5 of 9Figure 5 Effects of iQPR-H2O on lumbar spine (A), left knee (B), right knee (C), left femur (D), and right femur (E) BMD in OVX-SAMP8
mice. Two weeks after ovariectomy, OVX-SAMP8 mice were administered iQPR-H2O or unprocessed mineral water (control) at which time
baseline (T = 0) BMD values were determined. Thereafter, measurements were made every month for four months. Data represent means ± SD
of six mice.*P < 0.05, as determined by independent two-sample t-tests.
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days after the culture suggests that iQPR-H2O may have
promoted differentiation and mineralization of MC3T3-
E1 cells. In contrast to MC3T3-E1 cells, increased differ-
entiation of NIH3T3 cells was only observed in cells
cultured for 14 to 28 days in the presence of iQPR-H2O.
There were no statistically significant differences in ALP
expression between the iQPR-H2O-treated and control
cells at earlier time points (ie, within 7 days). This may
be explained by the cells being in a proliferative state,
which has been reported to delay differentiation [22],
within the first 7 days of culture.
Previous studies of bone remodeling have reported
that there are five stages to this process: activation,
resorption, reversal, formation, and quiescence. Progres-
sion from activation to resorption was found to take
place over two weeks, whereas three to four months
transpired between reversal and formation, and finally
quiescence [23,24]. In the present study, OVX-SAMP8
mice exhibited increased bone density after four months
treatment with iQPR-H2O. This time frame is compar-
able to that over which bone remodeling takes place.
H&E findings corroborated the BMD analysis findings.
Bone densities in iQPR-H2O-treated OVX-SAMP8
mice declined between zero and two months and then
rebounded during the third month. This presumably
reflects osteoclast resorption of old bone caused by
secretion of ALP, collagenase, lysosomal enzymes, and
proteases, followed by stimulation and recruitment of
osteoblasts into the site of osteoporosis. The formation
period is a slow phase, which takes approximately 35 to
40 days, which coincides with the BMD changes
observed over the four-month period in the present
study.
Of note, we found that left knee BMD, as determined
by bone densitometry was not significantly increased in
mice treated with iQPR-H2O compared with control.
This is a very puzzling finding for which we do not have
an explanation. Indeed, the lack of a significant change
in the left knee BMD as determined by bone densitome-
try is inconsistent with the findings for all other mea-
sures of BMD and bone density. We can only assume
that the observed BMD findings are a statistical
anomaly.
iQPR-H2O has approximately 60% less calcium than
unprocessed mineral water. It is well known that
Figure 6 Effect of iQPR-H2O on bone density as determined by H&E staining. Bone samples were obtained from OVX-SAMP8 mice given
iQPR-H2O or unprocessed mineral water (control) for four months and stained with H&E. (A) Representative images of (1) lumbar spine (left and
right panels), (2) left knee (top and bottom panels), and (3) right knee sections (top and bottom panels) from experimental and control mice,
respectively. (B) Bone density as quantified using Pixera Penguin 150CL Cooled CCD and software. (1) lumbar spine, (2) left knee, and (3) right
knee. Data represent means ± SD of six mice.*P < 0.05, as determined by independent two-sample t-tests.
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reduced calcium absorption, a higher rate of bone remo-
deling, and increased bone loss. Although we have not
assessed calcium homeostasis in mice treated with
iQPR-H2O, we do not believe that a 60% reduction in
the calcium content of drinking water would signifi-
cantly alter calcium homeostasis given that the vast
majority of calcium is obtained through the diet.
The mechanism by which iQPR-H2O influences bone
remodeling remains to be investigated. iQPR-H2Om a y
have increased the uptake of bone-associated elements
from the diet in the experimental animals. As compared
with unprocessed mineral water, iQPR-H2Oh a dr e l a -
tively high concentrations of magnesium, zinc, and sili-
con. Although the mechanism associating with the
change in the level of elements is still unknown, this
outcome is reproducible.
The importance of magnesium, zinc, and silicon and
their deficiencies on BMD has been demonstrated in
numerous studies. For example, magnesium deficiency
has been associated with hypertension, cardiac arrhyth-
mias, myocardial infarction, hypokalemia and hypocalce-
mia [25]. Epidemiological studies revealed that BMD of
the spine was significantly correlated with magnesium
intake in premenopausal women [26]. A cross-sectional
study reported a significant correlation between magne-
sium intake and hip BMD men aged 69-97 years [27].
Several studies have assessed the effect of magnesium
therapy for osteoporosis with varied results. Specifically, a
prospective study in which postmenopausal osteoporotic
women were given 250 mg of magnesium per day reported
a significant 2.8% increase in the bone density of the distal
radius at one year; however, no significant differences were
shown at two years, which may be due to the small number
(n = 10) of patients completing the study [28]. A retrospec-
tive study in which postmenopausal women received 200
mg of magnesium per day resulted in a small, non signifi-
cant 1.6% rise in lumbar spine bone density, and no differ-
ences were reported in the femur [29]. In another small
uncontrolled trial, a significant increase in the bone density
of the proximal femur and lumbar spine was found in
patients with gluten-sensitive enteropathy who received
504-576 mg of magnesium per day for two years [30].
Discrepant effects of zinc on bone progenitor cells
have been reported. For example, in bone marrow cells,
the highest ALP activity was observed when they were
cultured on the ceramics with 1.26 wt% zinc; the cera-
mics released zinc ions at concentrations ranging from
2.2 to 7.2 μg/mL into the culture medium [31]. Zinc
ions were incorporated into mineralized areas produced
by bone marrow cells. In addition, bone marrow cells
cultured in medium supplemented with 100 μMZ n C l 2
had significantly increased the ALP activity [31]. How-
ever, Popp et al. [32] reported no differences in rat bone
m a r r o ws t r o m a lc e l ln u m b e r ,A L Pa c t i v i t y ,t o t a lp r o t e i n
content, collagen synthesis, or matrix mineralization in
response to zinc supplementation.
Associations between silicon intake and BMD have
also been seen. The most readily bioavailable source of
silicon in the diet includes drinking water as well as
other fluids, accounting for ≥ 20% of the total dietary
intake [33]. Beneficial effects on bone and other connec-
tive tissues have been observed upon silicon supplemen-
tation. For example, dietary silicon intake is associated
with higher bone mineral density (BMD) [34]. In osteo-
porotic subjects, silicon supplementation with mono-
methyl trisilanol resulted in increased bone volume and
increases in femoral and lumbar spine BMD [29].
One limitation of this study is that increasing the
energy state of water after processing with steady device
of matter energy was not measured quantitatively, and
that the mechanism associating with the change in the
level of elements after the process was unknown. A
further limitation is that ALP activity levels were found
to increase with time in control MC3T3-E1 cells. This
f i n d i n gi sp u z z l i n ga n ds u g g e s t st h a tt h ec e l l sw e r e
undergoing spontaneous differentiation under the cul-
ture conditions without extracellular stimulation.
Conclusion
This is the first study to analyze the effect of iQPR-H2O
on bone remodeling in animals. iQPR-H2Oa m e l i o r a t e d
symptoms of osteoporosis and improved bone matrix.
Further studies are needed to analyze the mechanism by
which iQPR-H2Oe x e r t si t se f f e c t so no s t e o g e n e s i sa n d
to determine if the beneficial effects of iQPR-H2Oo n
osteogenesis are mediated through increased intake of
magnesium, zinc, or silicon. The effects of iQPR-H2O
on endogenous stem/progenitor cells in bone marrow
will also be analyzed. iQPR-H2O may ultimately prove
to be a useful treatment for osteoporosis.
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